Characterizing Psychological Consequences of Childhood Trauma
NCT ID: NCT00209105
Last Updated: 2013-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
113 participants
OBSERVATIONAL
2005-01-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Project 2: Psychoimmunology (PI A.H. Miller) Project 4: A Model of Learned Safety(PI: M. Davis) Project 6: Clinical Psychobiology(PI: C. Heim) Project 7: Children of Depressed Mothers(PI: Z. Stowe) Project 8: Functional Brain Imaging (PIs: H.S. Mayberg, G. Berns) Project 9: Structural \& Anatomical Connectivity Studies (PI: C.Kilts, X. Hu).
Project 2: The study seeks to examine the impact of psychosocial stress on neuroendocrine and immune signaling pathways of adult men and women with and without major depression who have experienced serious trauma (abuse, loss) during development. Serial blood samples will be collected at baseline and after an acute speech/math stressor (see Project 6). Assessments include IL-1alpha, and beta, IL-6, TNF alpha as well as DNS binding of relevant neuroendocrine-immune transcription factors, i.e. GR, CREB, and NFkB.
Project 4: This study uses a model of that allows for the independent evaluation of excitation and inhibition of fear-conditioning measured with the acoustic startle reflex. In addition, a dark-enhanced startle paradigm will be used that tests for anxiety. The effects of early-life stress will be evaluated in humans with and without major depressive disorder.
Project 6: This study assesses neuroendocrine and autonomic responses to stress and pharmacological challenge in subjects with and without major depression who have or have nor experienced early life stress. We seek to identify causes of variability in neuroendocrine-autonomic outcome after early life stress. To achieve this principle aim, we study the role of moderating and mediating factors including gender, genotype, type/timing of childhood trauma, as well as the role of adulthood trauma, comorbidity and cognitive dysfunction. The projects serves as a human subjects core for the other projects.
Project 7: This project characterizes effects of maternal depression on offspring in a longitudinal study. Women with and without depression will be prospectively followed through pregnancy and the first 6 months post-partum. Maternal stress and psychopathology, pregnancy and birth complications, medications and infants' physiological and behavioral stress responses will be assessed.
Project 8: This study uses PET and fMRI to characterize the impact of early-life stress on functional neural pathways mediating mood reactivity, self reference and reward-processing in patients with major depression. Cortical-limbic-striatal changes in cases with early stress but no psychopathology that define vulnerability to depression are also identified.
Project 9: This Project uses data obtained in Project 8 as well as diffusion tensor imaging to define the influence of early-life trauma on brain anatomical and functional connectivity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Participants who have experienced early-life trauma will undergo a series of diagnostic tests.
DEX-CRF stimulation test
1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
Psychosocial stress induction
Laboratory stress induction, no drug administration
Brain imaging of sad mood , self-reference, reward
Brain imaging
Acoustic startle
No drugs involved
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DEX-CRF stimulation test
1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
Psychosocial stress induction
Laboratory stress induction, no drug administration
Brain imaging of sad mood , self-reference, reward
Brain imaging
Acoustic startle
No drugs involved
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For participants assigned to the early-life stress group: repeated (once per month or more for at least year) sexual or physical abuse before the age of 13 years by a perpetrator at least 5 years older at the time
* For female participants: regular menstrual cycle and assessment in the early follicular phase as verified by sex steroid measures
Exclusion Criteria
* For all participants assigned to non-MDD groups: DSM-IV diagnosis of current MDD
* For all participants assigned to the group without early-life stress: major stress experiences before the age of 12 years, such as separation from parents, neglect, parental loss, accidents, severe illness, or natural disaster
* Significant medical illness, such as gastrointestinal, neurological, hormonal, heart, lung, kidney, liver, immunological or hematological disease, organic brain disease, or cancer as determined by history, physical examination, ECG, and laboratory tests
* Pregnant or breastfeeding
* Past or current presence of psychotic symptoms or bipolar disorder
* Current presence of psychoactive substance abuse/dependency or eating disorders
* Currently taking hormonal medication
* Taking psychotropic medication within 4 weeks of study entry
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Emory University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Becky Kinkead, PhD
Assocate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Becky Kinkead, PhD
Role: PRINCIPAL_INVESTIGATOR
Emory University SOM - Dept. of Psychiatry and Behavioral Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
General Clinical Research Center at Emory University Hospital
Atlanta, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
572-2004
Identifier Type: -
Identifier Source: secondary_id
DATR A3-NSC
Identifier Type: -
Identifier Source: secondary_id
IRB00021800
Identifier Type: -
Identifier Source: org_study_id